Results 51 to 60 of about 2,878,819 (307)

Classical Complement Pathway Inhibition in a Pediatric Patient With Refractory Immune Thrombocytopenia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric refractory immune thrombocytopenia (rITP) is generally characterized by persistent thrombocytopenia and failure to achieve a sustained response to multiple standard therapies. We report a 4‐year‐old female with congenital tufting enteropathy, post‐intestinal transplant patient on immunosuppressants, who developed severe rITP ...
Sarah Hsieh, Susmita Sarangi, Caileigh Pudela, Catherine M. Broome, Tara K. Suntum   +4 more
wiley   +1 more source

Engineering antibody therapeutics

Current Opinion in Structural Biology, 2016
The successful introduction of antibody-based protein therapeutics into the arsenal of treatments for patients has within a few decades fostered intense innovation in the production and engineering of antibodies. Reviewed here are the methods currently used to produce antibodies along with how our knowledge of the structural and functional ...
Chiu, Mark L, Gilliland, Gary L
openaire   +2 more sources

Therapeutic Antibodies in Multiple Sclerosis [PDF]

Neurodegenerative Diseases, 2007
ment of ever more effective drugs for the treatment of MS. The first immunomodulatory agents to benefit from the development mentioned above, interferon(Avonex , Betaferon/Betaseron , Rebif ) and glatiramer acetate (Copaxone ), have been on the market for more than a decade now and are established, safe, yet only mildly effective treatments for MS ...
Goebels, Norbert, Becher, Burkhard
openaire   +3 more sources

Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. [PDF]

, 2013
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action.
Duerr, Harald, Kettenberger, Hubert, Thomas, Markus, Imhof-Jung, Sabine, Fenn, Sebastian, Christian B Schiller, Harald Duerr, Julia J Griese, Griese, Julia J., Sebastian Fenn, Schiller, Christian B., Regula, Joerg Thomas, Sebastian Fenn, Schaefer, Wolfgang, Christian Klein, Klein, Christian, Christian Gassner, Hubert Kettenberger, Markus Thomas, Gassner, Christian, Julia J. Griese, Hopfner, Karl Peter, Wolfgang Schaefer, Christian B. Schiller, Karl-Peter Hopfner, Moelleken, Joerg, Hopfner, Karl-Peter, Joerg Moelleken, Joerg Thomas Regula, Sabine Imhof-Jung   +29 more
core   +2 more sources

Therapeutic Apheresis in Nigeria: A Multi‐Center Summary of Abstracts From the Inaugural Nigerian Society for Apheresis Scientific Meeting

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye, Chimezie Okwuonu, Evelyn Idam, Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Zinnah Aloziem, Blossom Amamchukwu, Patience Elimia, Mkpoikanabasi Obot‐Obot, Henry Mbakwe, Praises Maduagwuna, Olatunji Akinrodoye, Chiamaka Anyanwu, Benjamin Anyanwu, Adedamola Akinsiku, Oluwatoyin A. Akinsiku, Muzamil O. Hassan, Fatiu A. Arogundade, Olalekan E. Ojo, Homayemem Weli, Jesupelumi Adenihun, Aderemi Adelaja, Ebun Bamgboye, Olalekan Olatise, Ade E. Faponle, Ayoola Odeyemi, Michael Muoka, Stephen Asaolu, Qudrat Busari, Blessing Dawudu, Michael Naiyeju, Rasheed A. Balogun   +33 more
wiley   +1 more source

The Solution Structures of Two Human IgG1 Antibodies Show Conformational Stability and Accommodate Their C1q and FcγR Ligands. [PDF]

, 2015
The human IgG1 antibody subclass shows distinct properties compared with the IgG2, IgG3, and IgG4 subclasses and is the most exploited subclass in therapeutic antibodies. It is the most abundant subclass, has a half-life as long as that of IgG2 and IgG4,
Jayesh Gor, Dalby, PA, Gor, J, Heenan, RK, Gar Kay Hui, Hui, GK, Lucy E. Rayner, Paul A. Dalby, Stephen J. Perkins, Rayner, LE, Richard K. Heenan, Perkins, SJ   +11 more
core   +1 more source

The development and applications of polyclonal and monoclonal antibodies for the detection of illicit drugs in saliva samples [PDF]

, 2002
Anti-tetrahydrocannabinol (THC), anti-cocaine and anti-morphine polyclonal antibodies were produced. These antibodies were successfully applied to an ELISA format for the detection of THC, cocaine, and morphine in saliva samples. Monoclonal antibodies
Fanning, Lorna M.
core   +2 more sources

A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters

Frontiers in Immunology, 2020
The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing ...
Anna C. Fagre, John Manhard, Rachel Adams, Miles Eckley, Shijun Zhan, Juliette Lewis, Savannah M. Rocha, Catherine Woods, Karina Kuo, Wuxiang Liao, Lin Li, Adam Corper, Dilip Challa, Emily Mount, Christine Tumanut, Ronald B. Tjalkens, Tawfik Aboellail, Xiaomin Fan, Tony Schountz   +18 more
doaj   +1 more source

Effect of DFPP on Ferroptosis in Peripheral Blood CD14+ Monocytes of Hyperlipidemic Patients Involving the ACSL4/LPCAT3/ALOX5 Pathway

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Hyperlipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although statins are the cornerstone of lipid‐lowering therapy, their use may be limited in some patients by adverse effects. This study evaluated the possible impact of non‐drug treatment using double‐filtration plasmapheresis (DFPP) on CD14+
Yun Cheng, Lan Li, Qingmei Yang, Meipeng Wu   +3 more
wiley   +1 more source

Alternative Routes of Administration for Therapeutic Antibodies—State of the Art

Antibodies, 2022
Background: For the past two decades, there has been a huge expansion in the development of therapeutic antibodies, with 6 to 10 novel entities approved each year.
Aubin Pitiot, Nathalie Heuzé-Vourc’h, Thomas Sécher   +2 more
doaj   +1 more source